Acasti Pharma

ACST-X

Analysis and Opinions about ACST-X

Signal
Opinion
Expert
PARTIAL SELL
PARTIAL SELL
April 24, 2020
They have a product that uses fats to accelerate the effectiveness of other drugs. They have done tests at over 30 locations for a new drug that did not yield conclusive results. They are re-testing. He has sold a portion of his holdings.
Show full opinionHide full opinion
Acasti Pharma (ACST-X)
April 24, 2020
They have a product that uses fats to accelerate the effectiveness of other drugs. They have done tests at over 30 locations for a new drug that did not yield conclusive results. They are re-testing. He has sold a portion of his holdings.
BUY
BUY
March 16, 2020
It uses lipids having greater bio-availability to reduce cholesterol. The stock went through a hair cut recently. Testing results are being further investigated but are positive.
Show full opinionHide full opinion
Acasti Pharma (ACST-X)
March 16, 2020
It uses lipids having greater bio-availability to reduce cholesterol. The stock went through a hair cut recently. Testing results are being further investigated but are positive.
WAIT
WAIT
March 3, 2020
Develops CaPre to treat high cholesterol. One of the most promising companies. Strangely, the drug performed the same as the placebo. They'll have to raise more money. Right now, it's in no-man's land. Failure on a trial is devastating to a small company. Look at it in the fall.
Show full opinionHide full opinion
Develops CaPre to treat high cholesterol. One of the most promising companies. Strangely, the drug performed the same as the placebo. They'll have to raise more money. Right now, it's in no-man's land. Failure on a trial is devastating to a small company. Look at it in the fall.
HOLD
HOLD
February 7, 2020
They are working on testing a drug to use krill oil to help other drugs in the fight against cholesterol. Some recent research has been unclear among testers -- another test coming out in four months. He owns this personally.
Show full opinionHide full opinion
Acasti Pharma (ACST-X)
February 7, 2020
They are working on testing a drug to use krill oil to help other drugs in the fight against cholesterol. Some recent research has been unclear among testers -- another test coming out in four months. He owns this personally.
SELL
SELL
January 23, 2020
It highlights the pharma industry. In Canada there are a lot of tax credits that are applicable to Canadian Pharma companies. You can't say this is predictable. They went through the trials and it did not work. Phase three is for that. They still have some cash and some science. Stocks in this position usually flat lines for a while. He feels it is better to come out and get back in later.
Show full opinionHide full opinion
Acasti Pharma (ACST-X)
January 23, 2020
It highlights the pharma industry. In Canada there are a lot of tax credits that are applicable to Canadian Pharma companies. You can't say this is predictable. They went through the trials and it did not work. Phase three is for that. They still have some cash and some science. Stocks in this position usually flat lines for a while. He feels it is better to come out and get back in later.
SPECULATIVE BUY
SPECULATIVE BUY
December 27, 2019
They're working on a phase two test of a new drug, but the results are delayed, which has hammered the stock by half, though it's moved up 16% today. Results should be released in mid/late-January and he expects them to be positive. The drug will address a huge population who suffers high cholesterol. He sees a $10 target price, if the result is good and all goes well. Very speculative.
Show full opinionHide full opinion
Acasti Pharma (ACST-X)
December 27, 2019
They're working on a phase two test of a new drug, but the results are delayed, which has hammered the stock by half, though it's moved up 16% today. Results should be released in mid/late-January and he expects them to be positive. The drug will address a huge population who suffers high cholesterol. He sees a $10 target price, if the result is good and all goes well. Very speculative.
BUY
BUY
November 28, 2019
Quite likes the company. Potentially revolutionary drug called Capri has phase 3 trials coming up, and if those validate earlier phases, stock could have a lot of upside. Really likes it here. (Analysts’ price target is $5.52)
Show full opinionHide full opinion
Acasti Pharma (ACST-X)
November 28, 2019
Quite likes the company. Potentially revolutionary drug called Capri has phase 3 trials coming up, and if those validate earlier phases, stock could have a lot of upside. Really likes it here. (Analysts’ price target is $5.52)
BUY
BUY
November 25, 2019
They use the lipid from krill oil to strengthen action of another drug. Early indications seem very promising. The results should be out soon. One batch before the end of the year, and another in the new year. If the trial is successful, we could see a significant increase in the price.
Show full opinionHide full opinion
Acasti Pharma (ACST-X)
November 25, 2019
They use the lipid from krill oil to strengthen action of another drug. Early indications seem very promising. The results should be out soon. One batch before the end of the year, and another in the new year. If the trial is successful, we could see a significant increase in the price.
STRONG BUY
STRONG BUY
August 26, 2019
It's finally breaking out after going nowhere for a while. They're doing phase 3 trials now on their drug and should complete the results by December. That's why investors are pushing this stock up. He expects good results and be accretive. A $200 million company worth north of $1 billion. Caveat: biotech stocks are volatile.
Show full opinionHide full opinion
Acasti Pharma (ACST-X)
August 26, 2019
It's finally breaking out after going nowhere for a while. They're doing phase 3 trials now on their drug and should complete the results by December. That's why investors are pushing this stock up. He expects good results and be accretive. A $200 million company worth north of $1 billion. Caveat: biotech stocks are volatile.
COMMENT
COMMENT
August 1, 2019
A Top Pick of his son's. They use krill to give shrimp their pink colour. They are looking to combine this with a pharma drug to create synergies. If successful, the stock price analysts suggest it could go to $8 per share. They are doing FDA testing.
Show full opinionHide full opinion
Acasti Pharma (ACST-X)
August 1, 2019
A Top Pick of his son's. They use krill to give shrimp their pink colour. They are looking to combine this with a pharma drug to create synergies. If successful, the stock price analysts suggest it could go to $8 per share. They are doing FDA testing.
BUY
BUY
September 5, 2018

Pretty disappointing after last fall's announcement to have an Asian pharma company come in and get the rights to CaPre, their phase-3 development drug to treat cholesterol. It looked promising, but ACST hold off on the deal after a few new parties showed interest in CaPre. The market is disappointed the deal didn't happen and punished this stock. He believes this company could be worth $1 billion in two three years. The promise is still there, but you have to wait. Watch the phase 3 drug trials into next year.

Show full opinionHide full opinion
Acasti Pharma (ACST-X)
September 5, 2018

Pretty disappointing after last fall's announcement to have an Asian pharma company come in and get the rights to CaPre, their phase-3 development drug to treat cholesterol. It looked promising, but ACST hold off on the deal after a few new parties showed interest in CaPre. The market is disappointed the deal didn't happen and punished this stock. He believes this company could be worth $1 billion in two three years. The promise is still there, but you have to wait. Watch the phase 3 drug trials into next year.

TOP PICK
TOP PICK
March 29, 2018

A company with no revenue now. Drug developer. They are into phase 3 trials. A $33 million market cap company with half that in cash in their balance sheet. Probably going to be taken out by a large pharma once the drug is approved. (Analysts’ price target is $5.21)

Show full opinionHide full opinion
Acasti Pharma (ACST-X)
March 29, 2018

A company with no revenue now. Drug developer. They are into phase 3 trials. A $33 million market cap company with half that in cash in their balance sheet. Probably going to be taken out by a large pharma once the drug is approved. (Analysts’ price target is $5.21)

STRONG BUY
STRONG BUY
January 16, 2018

Got beaten up recently, because they just did a financing. (He has 3% of the financing.) A compelling opportunity and a great entry point. They are going to be initiating phase 3 trials this month. Just raised some money and have enough to do the trial now. In negotiations with a big Chinese Pharma in terms of licensing Asian rights. Has been presented with an opportunity for about $125 million deal with the Chinese, which they are still negotiating. They have the cash on the balance sheet, so there are no near-term financial pressures.

Show full opinionHide full opinion
Acasti Pharma (ACST-X)
January 16, 2018

Got beaten up recently, because they just did a financing. (He has 3% of the financing.) A compelling opportunity and a great entry point. They are going to be initiating phase 3 trials this month. Just raised some money and have enough to do the trial now. In negotiations with a big Chinese Pharma in terms of licensing Asian rights. Has been presented with an opportunity for about $125 million deal with the Chinese, which they are still negotiating. They have the cash on the balance sheet, so there are no near-term financial pressures.

BUY
BUY
September 27, 2017

A spin-out out of Neptune (NEPT-T), which still owns 35% of the company. There are positive developments going on and they are getting very close to going forward with phase 3. Discussions have been going on with the FDA. It’s fallen off the radar screen and there isn’t much in terms of analysts’ coverage. Expects there will be news this fall and winter which should really catalyze the stock. A good time to accumulate the stock.

Show full opinionHide full opinion
Acasti Pharma (ACST-X)
September 27, 2017

A spin-out out of Neptune (NEPT-T), which still owns 35% of the company. There are positive developments going on and they are getting very close to going forward with phase 3. Discussions have been going on with the FDA. It’s fallen off the radar screen and there isn’t much in terms of analysts’ coverage. Expects there will be news this fall and winter which should really catalyze the stock. A good time to accumulate the stock.

COMMENT
COMMENT
January 2, 2015

Acasti Pharma (APO-X) and Neptune Tech & Bioresource (NTB-T) comparison? The key for both companies is the use of krill to extract fish oil. The target would be for high lipids in blood. They can be taken alone or used in combination with statin drugs. The testing has been finished and it works. This stock is covered by only one analyst who is forecasting they are going to lose $0.06 in February year end, but will turn around and earn $0.22 in 2016. Speculative.

Show full opinionHide full opinion
Acasti Pharma (ACST-X)
January 2, 2015

Acasti Pharma (APO-X) and Neptune Tech & Bioresource (NTB-T) comparison? The key for both companies is the use of krill to extract fish oil. The target would be for high lipids in blood. They can be taken alone or used in combination with statin drugs. The testing has been finished and it works. This stock is covered by only one analyst who is forecasting they are going to lose $0.06 in February year end, but will turn around and earn $0.22 in 2016. Speculative.

Showing 1 to 15 of 18 entries

Acasti Pharma(ACST-X) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 5

Neutral - Hold Signals / Votes : 1

Bearish - Sell Signals / Votes : 2

Total Signals / Votes : 8

Stockchase rating for Acasti Pharma is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Acasti Pharma(ACST-X) Frequently Asked Questions

What is Acasti Pharma stock symbol?

Acasti Pharma is a Canadian stock, trading under the symbol ACST-X on the TSX Venture Exchange (ACST-CV). It is usually referred to as TSXV:ACST or ACST-X

Is Acasti Pharma a buy or a sell?

In the last year, 8 stock analysts published opinions about ACST-X. 5 analysts recommended to BUY the stock. 2 analyst recommended to SELL the stock. The latest stock analyst recommendation is PARTIAL SELL. Read the latest stock experts' ratings for Acasti Pharma.

Is Acasti Pharma a good investment or a top pick?

Acasti Pharma was recommended as a Top Pick by Robert McWhirter on 2020-04-24. Read the latest stock experts ratings for Acasti Pharma.

Why is Acasti Pharma stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Acasti Pharma worth watching?

8 stock analysts on Stockchase covered Acasti Pharma In the last year. It is a trending stock that is worth watching.

What is Acasti Pharma stock price?

On 2020-06-05, Acasti Pharma (ACST-X) stock closed at a price of $1.02.